Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Astrazeneca Plc ADR (AZN)
Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 196,064,192
  • Shares Outstanding, K 3,099,829
  • Annual Sales, $ 44,351 M
  • Annual Income, $ 3,288 M
  • 60-Month Beta 0.49
  • Price/Sales 4.44
  • Price/Cash Flow 12.47
  • Price/Book 5.29
Trade AZN with:

Options Overview Details

View History
  • Implied Volatility 20.44% ( +0.53%)
  • Historical Volatility 14.42%
  • IV Percentile 17%
  • IV Rank 17.88%
  • IV High 31.19% on 10/16/23
  • IV Low 18.11% on 08/01/23
  • Put/Call Vol Ratio 0.45
  • Today's Volume 2,514
  • Volume Avg (30-Day) 4,396
  • Put/Call OI Ratio 1.16
  • Today's Open Interest 134,074
  • Open Int (30-Day) 131,650

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.75
  • Number of Estimates 5
  • High Estimate 0.87
  • Low Estimate 0.69
  • Prior Year 0.69
  • Growth Rate Est. (year over year) +8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.65 +1.36%
on 11/13/23
65.11 -2.47%
on 12/04/23
+0.33 (+0.52%)
since 11/10/23
3-Month
61.73 +2.87%
on 10/27/23
70.94 -10.49%
on 10/17/23
-3.10 (-4.65%)
since 09/11/23
52-Week
61.73 +2.87%
on 10/27/23
76.56 -17.06%
on 04/25/23
-6.05 (-8.70%)
since 12/09/22

Most Recent Stories

More News
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?

It'll take a few years for its latest moves to pay off, assuming they do.

AZN : 63.50 (+0.40%)
Is Now the Right Time to Buy AstraZeneca Stock?

The pharmaceutical giant is making strident moves to compete in hot markets, but it's not a cheap stock.

AZN : 63.50 (+0.40%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

AVRN : 0.0125 (-30.56%)
ONCY : 1.3100 (-6.43%)
ONC.TO : 1.76 (-7.37%)
PFE : 28.64 (-0.49%)
ARVN : 33.80 (-1.05%)
OLMA : 11.44 (-5.69%)
AZN : 63.50 (+0.40%)
Roche's Bold Move into Obesity Treatment with $2.7B Carmot Therapeutics Takeover

Swiss pharmaceutical giant Roche (ROG) has marked a significant strategic shift by acquiring Carmot Therapeutics (CRMO), an obesity drug developer, for an upfront payment of $2.7 billion. This move positions...

ROG : 130.83 (+0.58%)
LLY : 584.04 (-2.34%)
AZN : 63.50 (+0.40%)
PFE : 28.64 (-0.49%)
ROIV : 9.93 (+1.02%)
300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Rates

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

AZN : 63.50 (+0.40%)
ONCY : 1.3100 (-6.43%)
ONC.TO : 1.76 (-7.37%)
DSNKY : 28.4100 (+3.05%)
GILD : 80.09 (+1.35%)
ARAY : 2.59 (-2.26%)
Investing in Hope: Biotech Innovations Targeting Increased Breast Cancer Rates in 2023

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

AZN : 63.50 (+0.40%)
ONCY : 1.3100 (-6.43%)
ONC.TO : 1.76 (-7.37%)
DSNKY : 28.4100 (+3.05%)
GILD : 80.09 (+1.35%)
ARAY : 2.59 (-2.26%)
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant

Could AstraZeneca be an under-rated buy right now?

LLY : 584.04 (-2.34%)
AZN : 63.50 (+0.40%)
3 No-Brainer Stocks to Buy With $1,000 Right Now

A modest amount of money can go a long way when it's invested in industry-leading businesses with sustained, long-term catalysts.

V : 256.52 (+0.30%)
AZN : 63.50 (+0.40%)
DIS : 92.20 (-0.67%)
3 stocks that crushed earnings estimates and still tanked

Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks

AZN : 63.50 (+0.40%)
SGHC : 2.99 (-0.33%)
WIX : 104.24 (+1.03%)
INTU : 586.66 (+2.22%)
AZN.LN : 10,096.000 (-0.26%)
AZNCF : 125.2000 (+0.11%)
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock

It might have a hard time finding a home in the market.

AZN : 63.50 (+0.40%)
NVO : 96.65 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 64.28
2nd Resistance Point 63.98
1st Resistance Point 63.62
Last Price 63.50
1st Support Level 62.96
2nd Support Level 62.66
3rd Support Level 62.30

See More

52-Week High 76.56
Fibonacci 61.8% 70.89
Fibonacci 50% 69.14
Fibonacci 38.2% 67.40
Last Price 63.50
52-Week Low 61.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar